Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cytotoxic T-cell lymphoma with muscle involvement and germline variants in inborn error of immunity-related genes: clinical and genetic insights from a case series.

Haematologica·2026

Same author

TP53 mutations and baseline lymphocytes indicate response to glofitamab in relapsed or refractory diffuse large B-cell lymphoma.

Annals of hematology·2026

Same author

Optimized interpretation of p53 immunohistochemistry for prediction of TP53 mutations and patient survival in DLBCL.

Clinical and experimental medicine·2026

Same author

UNC13D in Familial Hemophagocytic Lymphohistiocytosis and Beyond: Functional Mechanisms, Genetic Variants, Multisystem Disease Spectrum and Clinical Implications.

Scandinavian journal of immunology·2026

Same author

Anti-CD19 chimeric antigen receptor T cells in Evans syndrome of systemic lupus erythematosus.

Annals of hematology·2026

Same author

Single-cell analysis of UNC13D-mediated immune and dedifferentiation heterogeneity in acute myeloid leukemia and development of a prognostic model.

Translational cancer research·2026

Search research articles

Related Experiment Video

Updated: Mar 21, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Anti-CD19 CAR T cell therapy for refractory SLE-ITP.

Mengtao Li¹, Jiuliang Zhao¹, Zhi John Lu²

¹Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China.

Med (New York, N.Y.)

|March 19, 2026

Summary

This summary is machine-generated.

Anti-CD19 CAR T cell therapy shows promise for treating refractory systemic lupus erythematosus with immune thrombocytopenia (SLE-ITP). This innovative treatment demonstrated safety and efficacy in a small trial, offering hope for patients with this rare condition.

Keywords:

CAR-T SLE immune thrombocytopenia megakaryopoiesis single-cell translation to patients

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Related Experiment Videos

Last Updated: Mar 21, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Area of Science:

Immunology
Hematology
Oncology

Background:

Systemic lupus erythematosus (SLE) with immune thrombocytopenia (ITP) presents significant bleeding risks and poor survival rates.
Conventional and biologic therapies offer limited efficacy for SLE-ITP patients.
Refractory SLE-ITP necessitates novel therapeutic approaches.

Purpose of the Study:

To evaluate the safety and efficacy of anti-CD19 chimeric antigen receptor (CAR) T cell therapy in patients with refractory SLE-ITP.
To assess clinical response rates, including complete remission (CR) and partial remission (PR).

Main Methods:

A single-arm, dose-escalation trial involving six patients with refractory SLE-ITP.
Patients received anti-CD19 CAR T cells following lymphodepleting chemotherapy.
Safety and overall response rate were primary and secondary outcomes, respectively.

Main Results:

All six patients achieved a clinical response (CR or PR), with three reaching CR.
No severe adverse events like immune effector cell-associated neurotoxicity syndrome (ICANS) were observed.
Exploratory multi-omics revealed insights into B cell signaling and megakaryocyte maturation pathways in responders.

Conclusions:

Anti-CD19 CAR T cell therapy is a potentially safe and effective treatment for refractory SLE-ITP.
Further large-scale clinical trials are required to validate these preliminary findings.
This therapy offers a promising new avenue for managing this challenging autoimmune condition.